In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arrowhead buys another RNAi business, this time from Novartis, for $35mm

Executive Summary

For the second time, Arrowhead Research Corp. is taking on unwanted RNAi assets from Big Pharma; in this case, Novartis AG divested its RNAi R&D pipeline and related assets. Novartis, which will assign Arrowhead patents and patent applications, announced in April 2014 that it was significantly cutting internal drug discovery activities in the RNAi field.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Payment Includes Stock
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register